Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Unknown 3Completed 2Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia 2Neoplasm, Residual 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 1495Cisplatin 1431Paclitaxel 1339Radiotherapy 1308Carboplatin 1264Gemcitabine 1225Docetaxel 1134Bevacizumab 1068Fluorouracil 906Doxorubicin 799Dexamethasone 753Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 693Etoposide 674Irinotecan 639Filgrastim 624Nivolumab 585Cytarabine 585Leucovorin 582Vincristine 512Cetuximab 478Prednisone 477Bortezomib 472Trastuzumab 469Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 443Lenalidomide 434

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Histamine × Clear all
NCT01347996 2017-11-29

Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia

Cytovia, Inc.

Phase 4 Completed
84 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT00003991 2013-11-06

Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
360 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡